Q-Linea

Q-linea is a publicly traded infection diagnostics company with a commercialized, FDA-cleared product, the ASTar® system. Its core achievement is the development of a rapid phenotypic AST platform that reduces diagnostic time from up to 48 hours to about 6 hours, directly addressing the critical unmet need in sepsis management and antimicrobial stewardship. The company's strategy focuses on expanding the commercial footprint of ASTar, generating robust clinical and health-economic evidence, and pursuing regulatory clearances for new assays and geographies. Q-linea aims to establish its technology as a new standard of care in hospital microbiology labs globally.

The ASTar® system is a fully automated, phenotypic platform for rapid antimicrobial susceptibility testing (AST) that delivers Minimum Inhibitory Concentration (MIC) results directly from positive blood cultures in approximately six hours, featuring a controlled inoculum for high accuracy.

Q-linea competes with large automated AST incumbents (bioMérieux, BD) and other rapid AST innovators (e.g., Accelerate Diagnostics). Its key advantages are the speed of its AST-only platform (~6 hours), the provision of accurate MIC values via controlled inoculum, and a highly automated workflow requiring minimal hands-on time.